Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis
Status:
Recruiting
Trial end date:
2024-12-21
Target enrollment:
Participant gender:
Summary
Considering the accumulated data on the pathogenesis of multiple sclerosis, indicating a
significant role of B cells in the progression of the disease, the use of monoclonal
antibodies to CD20 antigen, administered intrathecally to achieve adequate B-lymphodepletion
in the barrier tissues can increase the duration of the recurrence-free course of autoimmune
diseases, suspend their progression, and also prevent clinical relapse when memory B cells
are detected.